Payment overview · 2025
General Payments
$172.46
9 reported records · 7 companies
Healthcare provider profile · identity verified
Robert Alan Wilson, MD
Allopathic & Osteopathic Physicians|Family Medicine · ERIN, TN · NPI 1699782557
Verified facts
What the public records show
CMS Open Payments records show Robert Alan Wilson, MD received $172.46 in general payments during 2025 across 9 reported records.
Novo Nordisk Inc accounted for 19.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.66 | 19.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.28 | 18.7% | 2 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $24.55 | 14.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.74 | 13.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.52 | 11.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.22 | 11.7% | 1 | 2025 |
| Ultragenyx Pharmaceutical Inc. | Unresolved — no canonical attribution shown | $17.49 | 10.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $172.46 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $33.66 | 2 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $24.55 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.74 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| Dojolvi Normalized: dojolvi |
Drug | Ultragenyx Pharmaceutical Inc. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 51 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
123 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
217 | 49 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 527 | 178 |
| Gabapentin | Gabapentin | 483 | 109 |
| Levothyroxine Sodium | Levothyroxine Sodium | 446 | 122 |
| Lisinopril | Lisinopril | 402 | 135 |
| Losartan Potassium | Losartan Potassium | 395 | 120 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 381 | 123 |
| Omeprazole | Omeprazole | 354 | 103 |
| Metformin Hcl | Metformin Hcl | 348 | 105 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 345 | 102 |
| Pantoprazole Sodium | Pantoprazole Sodium | 332 | 101 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 282 | 58 |
| Alprazolam | Alprazolam | 273 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 270 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 258 | 88 |
| Ozempic | Semaglutide | 217 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 204 | 66 |
| Pregabalin | Pregabalin | 204 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 197 | 65 |
| Simvastatin | Simvastatin | 193 | 64 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 192 | 32 |
| Meloxicam | Meloxicam | 190 | 72 |
| Furosemide | Furosemide | 182 | 67 |
| Montelukast Sodium | Montelukast Sodium | 179 | 42 |
| Tizanidine Hcl | Tizanidine Hcl | 176 | 54 |
| Famotidine | Famotidine | 166 | 55 |
| Duloxetine Hcl | Duloxetine Hcl | 157 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 156 | 55 |
| Buspirone Hcl | Buspirone Hcl | 150 | 47 |
| Allopurinol | Allopurinol | 149 | 52 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 149 | 32 |
| Carvedilol | Carvedilol | 146 | 51 |
| Celecoxib | Celecoxib | 144 | 52 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 142 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 139 | 51 |
| Sertraline Hcl | Sertraline Hcl | 137 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 129 | 31 |
| Trazodone Hcl | Trazodone Hcl | 127 | 41 |
| Citalopram Hbr | Citalopram Hydrobromide | 125 | 35 |
| Lorazepam | Lorazepam | 125 | 25 |
| Warfarin Sodium | Warfarin Sodium | 124 | 24 |
| Mounjaro | Tirzepatide | 123 | 30 |
| Oxycodone Hcl | Oxycodone Hcl | 122 | 24 |
| Diazepam | Diazepam | 118 | 21 |
| Januvia | Sitagliptin Phosphate | 117 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 116 | 24 |
| Prednisone | Prednisone | 113 | 52 |
| Methylprednisolone | Methylprednisolone | 111 | 89 |
| Eliquis | Apixaban | 104 | 28 |
| Potassium Chloride | Potassium Chloride | 104 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 99 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 93 | 71 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 91 | 24 |
| Metformin Hcl Er | Metformin Hcl | 85 | 30 |
| Spironolactone | Spironolactone | 85 | 20 |
| Bupropion Xl | Bupropion Hcl | 84 | 29 |
| Donepezil Hcl | Donepezil Hcl | 82 | 26 |
| Glimepiride | Glimepiride | 80 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 77 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 24 |
| Clonazepam | Clonazepam | 71 | 15 |
| Ibuprofen | Ibuprofen | 66 | 19 |
| Glipizide | Glipizide | 65 | 20 |
| Alendronate Sodium | Alendronate Sodium | 63 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 61 | 19 |
| Solifenacin Succinate | Solifenacin Succinate | 61 | 16 |
| Lovastatin | Lovastatin | 60 | 17 |
| Mirtazapine | Mirtazapine | 60 | 16 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 57 | 12 |
| Nifedipine Er | Nifedipine | 57 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 55 | 43 |
| Amitriptyline Hcl | Amitriptyline Hcl | 54 | 19 |
| Baclofen | Baclofen | 54 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 32 |
| Ondansetron Odt | Ondansetron | 53 | 11 |
| Memantine Hcl | Memantine Hcl | 52 | 14 |
| Farxiga | Dapagliflozin Propanediol | 51 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 39 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 18 |
| Temazepam | Temazepam | 50 | suppressed |
| Glipizide Er | Glipizide | 49 | 12 |
| Lamotrigine | Lamotrigine | 49 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 49 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 48 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 15 |
| Ezetimibe | Ezetimibe | 43 | 13 |
| Finasteride | Finasteride | 43 | 12 |
| Atenolol | Atenolol | 42 | 16 |
| Gemfibrozil | Gemfibrozil | 42 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 42 | 12 |
| Tramadol Hcl | Tramadol Hcl | 41 | 16 |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | 16 |
| Promethazine Hcl | Promethazine Hcl | 36 | 19 |
| Rizatriptan | Rizatriptan Benzoate | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | 14 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | 14 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 35 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 34 | suppressed |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Estradiol | Estradiol | 33 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | suppressed |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 12 |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 27 | 12 |
| Hydromorphone Hcl | Hydromorphone Hcl | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 13 |
| Ketoconazole | Ketoconazole | 22 | 12 |
| Telmisartan | Telmisartan | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 12 |
| Nucynta | Tapentadol Hcl | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Felodipine Er | Felodipine | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 15 |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Febuxostat | Febuxostat | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 14 |
| Sucralfate | Sucralfate | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Dexamethasone | Dexamethasone | 14 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Cholestyramine Light | Cholestyramine | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $172.46 · 9 records | Novo Nordisk Inc | APTIMA, BREZTRI, CAPVAXIVE, Dojolvi, ENFLONSIA, FARXIGA, GARDASIL 9, ROTATEQ, VAXNEUVANCE, VOQUEZNA, Wegovy, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error